Compare MD & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | AGIO |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 1996 | 2013 |
| Metric | MD | AGIO |
|---|---|---|
| Price | $26.77 | $35.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $20.50 | ★ $38.88 |
| AVG Volume (30 Days) | 737.9K | ★ 1.0M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.03 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,913,849,000.00 | $43,011,000.00 |
| Revenue This Year | $3.72 | $76.75 |
| Revenue Next Year | $2.62 | $170.73 |
| P/E Ratio | $72.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.84 | $22.24 |
| 52 Week High | $28.86 | $46.00 |
| Indicator | MD | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 44.85 |
| Support Level | $19.93 | $26.16 |
| Resistance Level | $28.86 | $36.07 |
| Average True Range (ATR) | 0.92 | 1.75 |
| MACD | -0.07 | -0.83 |
| Stochastic Oscillator | 92.06 | 6.93 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.